Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 40+ AI models, with 0% extra fees
Halozyme (HALO) Loses 9% on Weak Earnings
Halozyme (HALO) Loses 9% on Weak Earnings
Angelica Ballesteros
Thu, February 19, 2026 at 11:25 PM GMT+9 2 min read
In this article:
HALO
-0.97%
We recently published 10 Losing Stocks in an Otherwise Optimistic Market. Halozyme Therapeutics Inc. (NASDAQ:HALO) was one of the worst performers on Wednesday.
Halozyme snapped a two-day winning streak on Wednesday, shedding 9.01 percent to finish at $73.23 as investors digested a weak earnings performance in both the fourth quarter and full-year 2025.
In an updated report, Halozyme Therapeutics Inc. (NASDAQ:HALO) said that net income last year fell by 28.6 percent to $317 million from $444 million in 2024, despite revenues surging by 37 percent to $1.396 billion from $1.01 billion year-on-year.
5 Highest Paying Countries for Caregivers
Tyler Olson/Shutterstock.com
Total revenues were said to be primarily driven by a 52 percent jump in royalties and strong sales from Enhanze partner products.
In the fourth quarter, Halozyme Therapeutics Inc. (NASDAQ:HALO) swung to a net loss of $141.59 million from a $137 million net income in the same period a year earlier, but total revenues increased by 51.6 percent to $451.77 million from $298 million year-on-year.
Looking ahead, Halozyme Therapeutics Inc. (NASDAQ:HALO) is targeting to generate between $1.71 billion and $1.81 billion in revenues this year, as well as $2 billion in 2028.
Royalty revenues alone are projected at $1.13 billion to $1.17 billion, while adjusted EBITDA is expected to be at $1.125 billion to $1.205 billion. Non-GAAP diluted EPS is pegged at $7.75 to $8.25.
While we acknowledge the potential of HALO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey****.****
Terms and Privacy Policy
Privacy Dashboard
More Info